Robert's Feed
May 6, 2015
via Breakingviews

Alexion puts high stock to good use in biotech bid

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Alexion Pharmaceuticals is putting its high-flying stock to good use. The drugmaker’s $8.4 billion offer for rival Synageva BioPharma includes an astonishing 136 percent premium. The stonking price is based on the rare disease specialist’s view that investors underestimate its target’s value. Exchanging a chunk of pricey paper for those assets may be a savvy move.

May 6, 2015
via Breakingviews

Alexion puts high stock to good use in biotech bid

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Alexion Pharmaceuticals is putting its high-flying stock to good use. The drugmaker’s $8.4 billion offer for rival Synageva BioPharma includes an astonishing 136 percent premium. The stonking price is based on the rare disease specialist’s view that investors underestimate its target’s value. Exchanging a chunk of pricey paper for those assets may be a savvy move.

May 6, 2015
via Breakingviews

Would Microsoft really want to own Salesforce?

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Would Microsoft really want to own Salesforce.com? Buying the cloud-based, customer-service software maker could make businesses less likely to ditch Office. It might, however, cost Microsoft about $60 billion, a greater sum than it has spent on all its previous deals combined. A bold bet for boss Satya Nadella would create earnings dilution that irritates his shareholders.

May 6, 2015
via Breakingviews

Would Microsoft really want to own Salesforce?

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Would Microsoft really want to own Salesforce.com? Buying the cloud-based, customer-service software maker could make businesses less likely to ditch Office. It might, however, cost Microsoft about $60 billion, a greater sum than it has spent on all its previous deals combined. A bold bet for boss Satya Nadella would create earnings dilution that irritates his shareholders.

Apr 30, 2015
via Breakingviews

Salesforce’s slow growth may prompt hunt for buyer

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Salesforce.com’s slowing growth makes this a good time to seek a suitor. The $47 billion software outfit is on the market, according to Bloomberg. Oracle and Microsoft are looking to beef up cloud computing operations, putting them in the forefront of possible buyers. Founder Marc Benioff has been offloading shares steadily, and persistent losses and disappointing revenue growth could tempt him to hawk the whole thing.

Apr 28, 2015
via Breakingviews

Huge Apple payouts play catch-up with China growth

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Apple can’t pay out its readies fast enough. The $760 billion iPhone-making money machine is adding $50 billion more to its buyback plans. Throw in an increased dividend, and the total set to go back to shareholders between 2012 and 2017 is an eye-watering $200 billion.

Apr 27, 2015
via Breakingviews

Pharma Arbageddon fears keep traders on sidelines

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Fear is keeping traders on the sidelines of the latest pharma mega-deals. Teva Pharmaceutical Industries is offering $40 billion for Mylan, which has put $33.5 billion on the table for Perrigo. These would usually be catnip for M&A punters. But recent failures have made them skittish. And these two hostile battles come with cross-border complexity, antitrust and a poison pill. No wonder arbs are wary.

Apr 27, 2015
via Breakingviews

Pharma Arbageddon fears keep traders on sidelines

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Fear is keeping traders on the sidelines of the latest pharma mega-deals. Teva Pharmaceutical Industries is offering $40 billion for Mylan, which has put $33.5 billion on the table for Perrigo. These would usually be catnip for M&A punters. But recent failures have made them skittish. And these two hostile battles come with cross-border complexity, antitrust and a poison pill. No wonder arbs are wary.

Apr 21, 2015
via Breakingviews

Teva’s $40 bln hostile bid puts hope over reality

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Teva Pharmaceutical Industries’ $40 billion hostile bid is putting hope over reality. The Israeli drugmaker needs a deal to shore up falling sales. Smaller rival Mylan offers that and oodles of synergies. A tie-up, though, would face antitrust concerns, require high leverage and have to get around a powerful poison pill. No wonder the market is skeptical.

Apr 15, 2015
via Breakingviews

EU’s competition sprawl as worrying as Google’s

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The European Union’s competition sprawl is as worrying as Google’s. Trustbusters on Wednesday accused the $360 billion web giant of favoring its own shopping search results – and broadened the case to include its Android mobile operating system. Investigations and appeals may take a decade. Brussels is going down the same treacherous path as ever-expanding Google.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert